Pylarify (piflufolastat f-18)
Ended Awarded Last action
- Contract number
- 36C25524N0303
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 15
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,029,685
Award facts
- Contract value 100% obligated
- $1,029,685.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $1,200 | |
| Funding Only Action | $144,349 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $72,174 | |
| Funding Only Action | $270,654 | |
| Other Administrative Action | $0 | |
| Original award | $541,308 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $1.03M by Veterans Integrated Service Network 15 on June 20, 2024, for increased funding to support contract closeout of PYLARIFY (piflufolastat F-18) radiopharmaceutical supplies. This firm fixed-price delivery order, issued without set-aside designation, is scheduled for completion by June 19, 2025, and will be performed at the contractor's facility in North Billerica, Massachusetts. The award represents a task order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract, through which VISN 15 procures radiopharmaceutical products to support federal healthcare initiatives.
PYLARIFY is a radioactive diagnostic imaging agent utilized in positron emission tomography scans for the detection and localization of prostate cancer in veteran and military patient populations. The Department of Veterans Affairs, through its various Veterans Integrated Service Networks and in coordination with the Defense Health Agency, represents the primary federal customer for Progenics' radiopharmaceutical products. This delivery order continues the company's established role as a critical supplier of specialized nuclear medicine diagnostics across the VA healthcare system, building upon a substantial portfolio of existing blanket purchase agreements and indefinite delivery contracts valued at multimillion-dollar levels that extend through 2030.
Quick answers
Who was awarded contract 36C25524N0303?
36C25524N0303 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 15 (Veterans Health Administration) on June 20, 2024.
How much is contract 36C25524N0303 worth?
The government has obligated $1,029,685 on 36C25524N0303.
Is contract 36C25524N0303 an order under another contract?
Yes. 36C25524N0303 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25524N0303 competed?
The extent of competition for 36C25524N0303 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award